Court Rules for Biothera in Patent Infringement Suit

Court Rules for Biothera in Patent Infringement Suit

EAGAN, Minn. The U.S. DistrictCourt, District of Minnesota, in Minneapolis entered a judgment in favor ofBiothera in its patent infringement lawsuit against Nanjing, China-based FenchemEnterprises. The court ordered Fenchem to stop selling its GreenShieldingredient or any other yeast-derived beta-glucan product in the United States. Biothera originally filed the lawsuit in March 2005; similarlawsuits filed against Tromso, Norway-based Biotec Pharmacon ASA and its U.S. distributor Immunocorp regarding the product Immutol® arestill pending.

The court order protects our products and furtherstrengthens our ability to defend against patent infringers, said RichardMueller, president and chief executive officer (CEO) of Biothera(www.biotherapharma.com).